Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXM01 plus avelumab in progressive glioblastoma
NL-OMON48738Phase 2Active, not recruiting
- Sponsor
- Vaximm
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Live Vector Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vxm01 and avelumab in glioblastoma (GBM) (2 arms), sponsored by Vaximm. Primary endpoint: Safety and tolerability. Started Sep 2019; status: active, not recruiting.
02
Drugs
vxm01avelumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON48738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48738.